Aurinia's Q3 2026 Revenue Grows 14%, but IP and Demand Quality Questions Persist

What happened

Aurinia reported Q3 2026 total revenue of $83.7 million, up 14% year over year, and nine-month revenue of $244.6 million, up 19%. Net product sales, the primary growth driver, remained strong though the company did not disclose channel mix or unit metrics in the release. Growth has decelerated from the 20%+ pace seen in 2025, consistent with the base case scenario outlined in February 2026. The company remains a single-product story and faces an ongoing Paragraph IV ANDA challenge against its dosing-regimen patents. No update on litigation or pipeline progress was provided in the earnings snippet, leaving the key thesis risks unresolved.

Implication

The revenue beat supports the base case of 10-15% net product sales growth for 2026, but the lack of carton/patient data leaves uncertainty about demand durability. With the stock likely to remain rangebound until the ANDA litigation picture clarifies, the risk/reward at current levels is balanced. The $12 entry and $18 trim levels from the February 2026 master report remain intact. A break above $18 would require evidence of accelerating unit demand or favorable IP developments. Conversely, any adverse litigation signal would quickly pressure shares toward $10.

Thesis delta

The thesis delta is modest: the Q3 2026 revenue print aligns with the base case, but it does not resolve the core uncertainty around generic litigation and demand quality. The WAIT rating is maintained, as the stock's risk/reward remains balanced at current levels. Confirmation of patient-driven growth or a favorable IP update would shift the rating to BUY.